The IGHS Group welcomed, at the Oman International Hospital, the neurotech company REGEnLIFE
The IGHS Group welcomed, at the Oman International Hospital, the neurotech company REGEnLIFE that works at an advanced clinical stage on the treatment of neurodegenerative diseases.
REGEnLIFE and IGHS settled a strategic partnership to anticipate future developments related with the mission of the French company, offering innovative technologies that will improve the health and everyday lives of patients with debilitating neurological conditions such as Alzheimer's disease.
REGEnLife has as Chief Medical Officer and Chairman of the Scientific Advisory Board the Professor Jacques Touchon, former Dean of the Montpellier School of Medicine and International Key Opinion Leader on Alzheimer’s disease, that was present in Oman.
-
Innov.Cell ended its successful participation in CPHI 2024
Innov.Cell, a subsidiary of IGHS, ended its successful participation in CPHI 2024, which took place in Milan, with a positive outcome. This year, CPHI was attended by more than 62,000 people and around 2,400 exhibitors from 166 countries. Throughout the event, Innov.Cell met with several potential partners, from R&D, investors, and distributors covering more than 50 countries.
Read more -
OIH Introduces Revolutionary Treatment for Keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS)
Oman International Hospital is thrilled to announce the successful introduction of a groundbreaking procedure designed to treat keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS). This innovative treatment marks a significant advancement in ophthalmology, offering new hope to patients suffering from this debilitating corneal disorder.
Read more